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Abstract
Background: Integrin activation in response to inside-out signaling serves as the basis for rapid leukocyte arrest on
endothelium, migration, and mobilization of immune cells. Integrin-dependent adhesion is controlled by the
conformational state of the molecule, which is regulated by seven-transmembrane Guanine nucleotide binding
Protein-Coupled Receptors (GPCRs). a4b1-integrin (CD49d/CD29, Very Late Antigen-4, VLA-4) is expressed on
leukocytes, hematopoietic progenitors, stem cells, hematopoietic cancer cells, and others. VLA-4 conformation is
rapidly up-regulated by inside-out signaling through Gai-coupled GPCRs and down-regulated by Gas-coupled
GPCRs. However, other signaling pathways, which include nitric oxide-dependent signaling, have been implicated
in the regulation of cell adhesion. The goal of the current report was to study the effect of nitric oxide/cGMP
signaling pathway on VLA-4 conformational regulation.
Results: Using fluorescent ligand binding to evaluate the integrin activation state on live cells in real-time, we
show that several small molecules, which specifically modulate nitric oxide/cGMP signaling pathway, as well as a
cell permeable cGMP analog, can rapidly down-modulate binding of a VLA-4 specific ligand on cells pre-activated
through three Gai-coupled receptors: wild type CXCR4, CXCR2 (IL-8RB), and a non-desensitizing mutant of formyl
peptide receptor (FPR ΔST). Upon signaling, we detected rapid changes in the ligand dissociation rate. The
dissociation rate after inside-out integrin de-activation was similar to the rate for resting cells. In a VLA-4/VCAM-
1-specific myeloid cell adhesion system, inhibition of the VLA-4 affinity change by nitric oxide had a statistically
significant effect on real-time cell aggregation.
Conclusions: We conclude that nitric oxide/cGMP signaling pathway can rapidly down-modulate the affinity state
of the VLA-4 binding pocket, especially under the condition of sustained Gai-coupled GPCR signaling, generated
by a non-desensitizing receptor mutant. This suggests a fundamental role of this pathway in de-activation of
integrin-dependent cell adhesion.
Background
Integrins are ubiquitous cell adhesion molecules that
play an essential role in the regulation of leukocyte traf-
fic, stem cell mobilization and homing, immune
responses, development, hemostasis, and cancer [1-3].
On the cell surface at rest, a variety of integrin exhibit a
non-adhesive inactive state and multiple signaling
cascades are capable of rapidly and reversibly regulating
integrin-dependent cell adhesion. Typically, this regula-
tion is achieved without altering the integrin expression
level. Conformational changes within the molecule,
together with a spatial reorganization of integrins, are
responsible for the rapid modulation of cell adhesion
[1,4-6]. Understanding signaling pathways that regulate
activation and, especially, inactivation of integrin-
mediated cell adhesion is crucial, as integrins are impli-
cated in many human diseases [7-9]. Several existing
and emerging drugs for treating inflammatory diseases,
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and others specifically target integrin molecules [10-12].
Moreover, interfering with integrin activation by target-
ing “the final steps of activation process” is envisioned
as a novel approach for therapeutic intervention in
integrin-related pathologies [13].
Very Late Antigen-4, VLA-4, (a4b1-integrin, CD49d/
CD29) is expressed on a majority of peripheral blood
leukocytes, hematopoietic progenitors and stem cells, as
well as hematopoietic cancer cells [2,14,15]. VLA-4 has
the potential to exhibit multiple affinity (conformational)
states that mediate tethering, rolling, and firm arrest on
VCAM-1 (CD106, Vascular Cell Adhesion Molecule-1)
[16-18]. The VLA-4 conformational state is regulated by
G protein-coupled receptors (GPCRs) that operate as
receptors for multiple chemokines and chemoattrac-
tants. The majority of receptors activating VLA-4 are
Gai-coupled GPCRs that function by inhibiting adeny-
late cyclase and inducing calcium mobilization. These
i n c l u d eC X C R 2 ,C X C R 4 ,a n do t h e r s[ 1 9 ] .G ai-coupled
GPCRs activate integrin by triggering the so-called
inside-out signaling pathway [20], which leads to a rapid
increase in ligand binding affinity that is translated into
the “rapid development of firm adhesion” [18].
Recently, in addition to the inside-out integrin activa-
tion pathway, we described a de-activation signaling
pathway that can rapidly down-regulate the binding affi-
nity state of the VLA-4 binding pocket. Two Gas-coupled
GPCRs (histamine H2 receptor and b2-adrenergic recep-
tors), an adenylyl cyclase activator, and a cell permeable
analog of cAMP showed the ability to regulate VLA-4
ligand binding affinity as well as VLA-4/VCAM-1 depen-
dent cell adhesion on live cells in real-time [21]. Based
on these findings we hypothesized that other de-activat-
ing inside-out signaling pathways might exist. Review of
the literature indicated that nitric oxide/cGMP-depen-
dent signaling pathway could be one of them.
Both cAMP/PKA and cGMP/PKG signaling pathways
play an inhibitory role in GPCR-induced platelet aggrega-
tion and adhesion [22], which is known to be critically
dependent on the activation state of platelet integrins
[23,24]. Cyclic nucleotide dependent kinases (PKA and
P K G )s h a r eas t r o n gs e q u e n c eh o m o l o g ya n de x h i b i t
overlapping substrate specificity [25]. Nitric oxide signal-
ing is critical for hematopoietic progenitor and stem cell
mobilization [26,27], a physiological process that is criti-
cally dependent on the interaction between VLA-4 integ-
rin and VCAM-1 [28-32]. Nitric oxide is also shown to
antagonize GPCR signaling in muscle cells [33]. The
molecular mechanism by which nitric oxide regulates
integrin-dependent adhesion is under active investiga-
tion. Several reports indicate that direct s-nitrosylation of
cytoskeletal proteins [34], or integrins themselves [35],
can be involved in the regulation of integrin-dependent
adhesion. The goal of the current manuscript was to
investigate the effects of exogenous nitric oxide, and
other cGMP pathway regulators on VLA-4 conforma-
tional regulation on live cells in real-time.
We found that the addition of a nitric oxide donor
can rapidly induce dissociation of the VLA-4 specific
ligand after cellular activation by any of three GPCRs
(CXCR4, CXCR2, and FPR). The effect of nitric oxide
was also mimicked by a NO-independent cGMP-cyclase
activator, as well as a cell permeable analog of cGMP.
This indicates that the integrin deactivation mechanism
is intracellular, and suggests that deactivation is not
related to direct s-nitrosylation. We also detected rapid
changes in the dissociation rate constant (koff)o ft h e
VLA-4 specific ligand. As shown previously, modulation
of the koff directly correlates with changes in the VLA-4
ligand binding affinity [14,17]. Finally, using a VLA-4/
VCAM-1 specific cell adhesion system, we showed that
treatment of cells with a nitric oxide donor diminished
GPCR activated cell adhesion to the level of unstimu-
lated (untreated) cells. Taken together, our results indi-
cate that the NO/cGMP signaling pathway can actively
down-regulate the affinity of the VLA-4 ligand binding
pocket. This observation provides a molecular mechan-
ism for the anti-adhesive activity of nitric oxide donors
and drugs that modulate cGMP signaling pathway.
Results
Small molecule probes for dissecting the nitric oxide/
cGMP pathway
The nitric oxide/cGMP signaling pathway has been
described in mature leukocytes, platelets, and hemato-
poietic progenitors. It is composed of soluble guanylyl
cyclase (GC) that serves as an intracellular receptor for
nitric oxide (Figure 1). Upon binding to NO-sensitive
guanylyl cyclase, nitric oxide induces a conformational
change resulting in the activation of the enzyme [36],
and conversion of GTP to cGMP. Cyclic guanosine
monophosphate binding leads to the subsequent activa-
tion of the cGMP dependent kinase PKG that phosphor-
ylates multiple substrates, and participates in the
regulation of platelet adhesion and aggregation [37].
To study the effects of nitric oxide/cGMP signaling in
leukocytes, we selected three small molecules that speci-
fically target this pathway (Figure 1). Diethylamine
NONOate can be described as a complex of diethyla-
mine with nitric oxide. It is unstable in aqueous solution
and used as nitric oxide donor [38]. BAY 41-2272 is an
activator of soluble guanylyl cyclase, which stimulates
cGMP production through an NO-independent mechan-
ism [39,40]. N
2,2’-O-dibutyrylguanosine 3’,5’-cyclic
monophosphate is a cell permeable cGMP analog that
activates protein kinase G [41]. These molecules are
shown to stimulate the three initial consecutive steps of
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mimic NO-dependent signaling.
Nitric oxide donor induces rapid decrease in the binding
of VLA-4 specific ligand
Previously, we described and characterized in detail a
model ligand an LDV-FITC containing small molecule
([14,42-44], and references therein) for the detection
of VLA-4 conformational regulation. This VLA-4 spe-
cific fluorescent probe was based on a highly specific
a4b1-integrin inhibitor BIO1211, which contains the
Leu-Asp-Val (LDV) ligand binding motif from the
alternatively spliced connecting segment-1 (CS-1) pep-
tide of cellular fibronectin [17,45]. We established that
integrin affinity changes, detected using this probe,
vary in parallel with the natural VLA-4 ligand, human
VCAM-1 [46]. For real-time detection of rapid integrin
conformational changes, cells were treated with LDV-
FITC (Figure 2, first arrow), which was added after
establishing a baseline for unstained cells, indicated on
Figure 1 NO/cGMP signaling cascade and small molecules that modulate this pathway, used in the current study.N i t r i co x i d e ,
generated by nitric oxide synthase, diffuses across the plasma membrane and through the cytoplasm. In leukocytes NO reacts with the active
site of guanylyl cyclase (guanylate GC), and stimulates the production of the intracellular mediator cyclic GMP (cGMP). Next, cGMP interacts with
the cGMP-dependent protein kinase (PKG), which phosphorylates multiple substrates, and participates in signal propagation. Cyclic nucleotide
phosphodiesterases (PDEs, not shown) can rapidly hydrolyze cGMP and terminate signal propagation. The NO/cGMP signaling pathway can be
specifically targeted using small molecules. The nitric oxide donor provides an exogenous source of NO. The activator of soluble guanylyl cyclase
binds to GC, and induces enzyme activation in the absence of NO. The cell permeable analog of cGMP diffuses across the plasma membrane,
and thus, activates cGMP-dependent signaling.
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Figure 2 Effect of nitric oxide addition on binding and dissociation of the LDV-FITC probe on U937 cells, treated with different
Gai-coupled receptor ligands. LDV-FITC probe binding and dissociation on U937 cells stably transfected with different GPCRs plotted as mean
channel fluorescence (MCF) versus time. A, The experiment involved sequential addition of fluorescent LDV-FITC probe (4 nM, below saturation,
added 2 min prior to addition of Gai-coupled receptor ligand, fMLFF, 100 nM), and different concentrations of DEA-NONOate (nitric oxide
donor). Dashed line indicates the non-specific binding of the LDV-FITC probe determined using an excess of unlabelled LDV competitor
(as shown in Fig. 2D,E). B, The experiment involved sequential addition of fluorescent LDV-FITC probe (4 nM), CXCL12/SDF-1 (12 nM), and
DEA-NONOate (250 μM, nitric oxide donor) or vehicle (control). Rapid and reversible binding of the probe reflects the VLA-4 affinity change [14].
C, The experiment involved sequential addition of the fluorescent LDV-FITC probe (4 nM), CXCL8/IL-8 (20 nM), and DEA-NONOate (250 μM, nitric
oxide donor) or vehicle (control). D, The experiment involved sequential addition of the DEA-NONOate (250 μM, nitric oxide donor) or vehicle
(control) at the 0 time point, and the fluorescent LDV-FITC probe (4 nM), CXCL12/SDF-1 (12 nM). Excess unlabelled competitor LDV (1 μM) is
added at the end of the experiment to determine the non-specific binding of the probe (panels D, and E). E, The experiment involved
sequential addition of DEA-NONOate (250 μM, nitric oxide donor) or vehicle (control) at the 0 time point, and the fluorescent LDV-FITC probe
(4 nM), CXCL8/IL-8 (20 nM) (arrows). According to the unpaired t test, the means are significantly different (p<0.05) at the peak of activation
(marked on panels D and E as “*”), and at the steady state (marked on panels B-E as “**”). Experiments shown in the different panels were
performed using different instruments, and therefore MCF values are not identical.
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Page 4 of 12Figure 2A as “autofluorescence”.N e x t ,d a t aw e r e
acquired for 2-3 minutes, and cells were activated with
fMLFF (high affinity FPR ligand), CXCL12/SDF-1
(CXCR4 ligand), or CXCL8/IL-8 (CXCR2 ligand), for
FPR, CXCR4, CXCR2 transfected cells, respectively (Fig-
ure 2A, B, and 2C). The concentration of the LDV-
FITC probe used in the experiments (4 nM) was below
the dissociation constant (Kd) for its binding to resting
VLA-4 (low affinity state, Kd ~1 2n M ) ,a n da b o v et h e
Kd for physiologically activated VLA-4 (high affinity
state, Kd ~ 1-2 nM) [14]. Therefore, the transition
from the low affinity to the high affinity receptor state
led to increased binding of the probe (from ~25% to
~70-80% of receptor occupancy, as calculated based on
the one site binding equation). The change in occu-
pancy was detected as a rapid increase in the mean
channel fluorescence (MCF). This signal increase was
sustained for the case of a non-desensitizing mutant of
FRP (Figure 2A), and reversible for the wild-type
receptors (CXCR4, and CXCR2, Figure 2B,C). Next,
cells were treated with the nitric oxide donor, or vehi-
cle (control). Acquisition was re-established, and data
were acquired continuously for up to 720-840 s. Addi-
tion of the nitric oxide donor resulted in a rapid and
dose-dependent decrease in the binding of the VLA-4
specific ligand. In the absence of receptor desensitiza-
tion, the effect of nitric oxide was more evident in
cells transfected with a non-desensitizing mutant of
FPR (vehicle, Figure 2A) [47,48]. However, the effect of
the nitric oxide donor was statistically significant for
both wild-type GPCRs. A faster and more pronounced
signal decrease was detected (see black lines in Figure
2B, 2C). To emphasize statistically the difference
between control and experimental samples, standard
errors of mean are indicated using error bars for every
experimental point in Figure 2B, 2C, 2D, 2E.
Next, we studied the effect of nitric oxide donor added
prior to cell activation. DEA-NONOate was added at the
0 time point as indicated by the arrow (Figure 2D, 2E).
This resulted in a significant decrease in the magnitude
of the response for both SDF-1 and IL-8 treated cells.
Moreover, the effect of nitric oxide can be detected
prior to cell activation. This suggests that at rest a small
number of VLA-4 molecules exists in the activated con-
formation, and addition of nitric oxide donor deacti-
vates these integrins. It worth noting that the
nonspecific binding of the LDV-FITC probe remained
identical for both control and treated samples (compare
sample fluorescence after addition of LDV). Thus, the
nitric oxide donor rapidly decreased binding of the
VLA-4 specific fluorescent ligand after cell activation
through three Gai-coupled GPCRs. Pretreatment with
the nitric oxide donor significantly diminished the mag-
nitude of the response.
Activator of soluble guanylyl cyclase induces a dose-
dependent decrease in the binding of the VLA-4 specific
ligand
To confirm that the effect of nitric oxide can be
mimicked using a nitric oxide-independent activator of
soluble guanylyl cyclase, we repeated the experiments
shown in Figure 2A using BAY 41-2272 (Figure 3A).
Cells, transfected with a non-desensitizing mutant of
FPR, were sequentially treated with LDV-FITC (4 nM),
fMLFF, vehicle, or indicated concentrations of the solu-
ble guanylyl cyclase activator. We observed a significant
decrease in LDV-FITC binding, comparable to the effect
induced by the nitric oxide donor (Figure 2A). However,
the decrease in LDV-FITC binding was partially reversi-
ble. This phenomenon can be rationalized, in terms of
the proposed feedback loops that regulate cGMP pro-
duction. Intracellular cGMP can directly stimulate the
catalytic activity of several cyclic nucleotide phospho-
diesterases (PDEs) that hydrolyze cGMP [49-51].
Another possibility is activation of PDEs through phos-
phorylation by cGMP-dependent protein kinase (PKG)
(Figure 1) [50-53].
Next, we studied the effect of the nitric oxide-inde-
pendent activator of soluble guanylyl cyclase added prior
to cell activation. BAY 41-2272 was added at the 0 time
point as indicated by the arrow (Figure 3B, 3C). This
resulted in a decrease in the magnitude of the response
for both SDF-1 and IL-8 treated cells in a manner com-
parable to the effect of nitric oxide donor. Similarly, the
effect of activator of soluble guanylyl cyclase can be
detected prior to cell activation. Thus, the nitric oxide-
independent activator of soluble guanylyl cyclase
induces a dose-dependent decrease in binding of the
VLA-4 specific ligand, and pretreatment with the activa-
tor of soluble guanylyl cyclase significantly diminished
the magnitude of the response after activation.
Dissociation rate analysis revealed rapid changes in the
dissociation rate of the VLA-4 specific ligand
As shown previously, for different states of VLA-4 affi-
nity, the LDV-FITC equilibrium dissociation constant
Kd varied inversely with the dissociation rate constant
(koff). This implies that the ligand association rate con-
stant is essentially independent of receptor conformation
(for example see Table I in [17]), or Table I in [14]).
Therefore, the dissociation rate analysis can be used to
assess the affinity state of the VLA-4 integrin binding
pocket.
To saturate the majority of low affinity sites, cells
transfected with a non-desensitizing mutant of FPR
were preincubated with a higher concentration of the
VLA-4 specific ligand (25 nM). Since the Kd for the low
affinity state is ~12 nM (Table I in [14]), at 25 nM
~70% of sites are occupied before activation. Next, an
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Figure 3 Effect of guanylyl cyclase activator on binding and dissociation of the LDV-FITC probe on U937 cells, treated with different
Gai-coupled receptor ligands. LDV-FITC probe binding and dissociation on U937 cells stably transfected with different GPCRs plotted as mean
channel fluorescence (MCF) versus time. A, The experiment involved sequential addition of the fluorescent LDV-FITC probe (4 nM, below
saturation, added 2 min prior to addition of the Gai-coupled receptor ligand, fMLFF, 100 nM), and different concentrations of BAY 41-2272
(guanylyl cyclase activator). B, The experiment involved sequential addition of the BAY 41-2272 (100 μM, guanylyl cyclase activator) or vehicle
(control) at the 0 time point, and the fluorescent LDV-FITC probe (4 nM), and CXCL12/SDF-1 (12 nM). C, The experiment involved sequential
addition of BAY 41-2272 (100 μM, guanylyl cyclase activator) or vehicle (control) at the 0 time point, and the fluorescent LDV-FITC probe (4 nM),
and CXCL8/IL-8 (20 nM). The means are significantly different (p<0.05) at the peak of activation (marked on panels B and C as “*”), and at the
steady state (marked in panels B and C as “**”). D, Kinetic analysis of binding and dissociation of the LDV-FITC probe. Cells were sequentially
treated with the LDV-FITC probe (25 nM, near saturation), the Gai-coupled receptor ligand (fMLFF, 100 nM), BAY 41-2272 (guanylyl cyclase
activator, 50 μM). At time points indicated by arrows, cells were treated with excess unlabeled LDV containing small molecule (2 μM), and the
dissociation of the fluorescent molecule was followed. Dissociation rate constants (koff) were obtained by fitting dissociation curves to a single
exponential decay equation. E, Dissociation rate values, obtained in experiments analogous to panel D, summarized as a bar graph showing
mean and SEM (n=4). Colors of the dissociation curves in panel D and bars on panel E are matching. The difference between koffs for “resting”
and “fMLFF activated”, and between “fMLFF activated” and “fMLFF activated and treated with BAY 41-2272” is statistically significant (P < 0.05) as
calculated by one-way ANOVA.
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Figure 3D as “LDV block”) is added to induce dissociation
of the LDV-FITC probe. After activation by fMLFF,
because of the rapid affinity change, little additional bind-
ing of the probe was seen (Figure 3D, green and red lines).
Addition of the nitric oxide-independent activator of the
soluble guanylyl cyclase returned the binding of the probe
to a level similar to the binding before fMLFF addition.
Next, the regions of the ligand-binding curves corre-
sponding to the dissociation of the LDV-FITC probe
were fitted to a single exponential decay equation. The
resulting dissociation rate constants (koff,s
-1) are shown
graphically in Figure 3E. At rest, the majority of the
VLA-4 molecules exhibit rapid probe dissociation, corre-
sponding to the low affinity state of the ligand binding
pocket (Figure 3D, 3E, blue curve “LDV-FITC, LDV
block”,k off ~0 . 0 4±0 . 0 0 1s
-1). After cell activation by
fMLFF, the dissociation rate was significantly slower
(Figure 3D, 3E, red curve “LDV-FITC, fMLFF, LDV
block”,k off ~ 0.018 ± 0.0001 s
-1). The slower koff corre-
sponds to higher ligand binding affinity [14,17,46]. After
the addition of the nitric oxide-independent activator of
soluble guanylyl cyclase, dissociation rates were compar-
able to the rate for the resting state (Figure 3D, 3E,
green curve “LDV-FITC, fMLFF, BAY 41-2272, LDV
block”,k off ~ 0.036 ± 0.0007 s
-1). This suggests that acti-
vation of guanylyl cyclase can actively down-regulate the
affinity state of the VLA-4 integrin ligand binding
pocket, even under the condition with the continuously
signaling non-desensitizing GPCR mutant. The affinity
state induced by guanylyl cyclase activator was quantita-
tively similar to the resting state before activation. The
resting VLA-4 conformation on U937 cells exhibits the
lowest physiological affinity. It is worth noting, that this
result is comparable to the effect of Gas-coupled
GPCRs on VLA-4 conformation (compare Figure 3D in
the current manuscript and Figure 2C, 2D in [21]). This
result is especially interesting in light of the structural
relationship of the two second messengers cAMP and
cGMP, originating from these signaling pathways.
Dibutyrylguanosine 3’,5’-cyclic monophosphate induces
rapid and reversible changes in the binding of the VLA-4
specific ligand
Next, we studied the effect of the cell permeable analog
of cGMP on real-time binding of the LDV-FITC probe
(Figure 4). Addition of dbcGMP induced a dose-depen-
dent decrease in the binding of the probe. However, the
effect of dbcGMP was reversible. These kinetics are
compatible with negative feedback loops that regulate
cGMP dependent signaling. Activation of PDEs directly
by cGMP binding, or indirectly after being phosphory-
lated by a cGMP dependent kinase (PKG), has been pre-
viously reported [49-53].
Thus, all three probes specifically targeting the NO/
cGMP pathway (the nitric oxide donor, the nitric oxide-
independent activator of soluble guanylyl cyclase, and
the cell permeable analog of cGMP) were found to
decrease binding of the VLA-4 specific ligand, with
similar kinetics, after cell activation through Gai-
coupled GPCRs. To study the effects of NO/cGMP sig-
naling on cell aggregation, we used a model system,
consisting of U937 cells, stably transfected with GPCR
in the experiments described above (Figures 2, 3, 4), and
a mouse melanoma cell line stably transfected with
human VCAM-1. The unlabelled VLA-4 specific ligand
(LDV), analogous to the LDV-FITC probe, was used to
identify VLA-4/VCAM-1 specific cell aggregation. This
model system has been described and characterized pre-
viously [42,46,54,55].
The effect of nitric oxide/cGMP signaling pathway
activation on VLA-4 -VCAM-1 dependent cell adhesion
Prior to the experiment, individual cell populations were
stained with either of two fluorescent dyes (red and
green). Next, the cell populations were mixed, and the
appearance of double positive events, representing cellular
aggregates, was followed in real-time by flow cytometry
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Figure 4 Effect of the cell permeable analog of cGMP on
binding and dissociation of the LDV-FITC probe on U937 cells
stably transfected with the non-desensitizing mutant of FPR.
LDV-FITC probe binding and dissociation on U937 cells stably
transfected with the non-desensitizing mutant of FPR plotted as
mean channel fluorescence (MCF) versus time. The experiment
involved sequential addition of the fluorescent LDV-FITC probe
(4 nM, below saturation, added 2 min prior to addition of the
Gai-coupled receptor ligand, fMLFF, 100 nM), and different
concentrations of dibutyrylguanosine 3’,5’-cyclic monophosphate
(cell permeable cGMP analog) (arrows). Control cells were treated
with vehicle. The MCF value corresponding to cell autofluorescence
is indicated by the horizontal arrow. Dashed line indicates the non-
specific binding of the LDV-FITC probe determined using excess
unlabelled LDV competitor (as shown on Figure 3B). Rapid and
reversible binding of the probe reflects the VLA-4 affinity change
[14]. Curves are means out of two independent determinations
calculated on a point-by-point basis (n = 2).
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Page 7 of 12(see Figure 1, 2, 3 in [55] for method details). Because
nitric oxide represents a “natural” signaling molecule, and
the effect of nitric oxide was not reversible during the first
several hundred seconds after treatment (Figure 2A), for
aggregation experiments cell were treated with the NO-
donor (Figure 5). Resting (unstimulated) cells showed a
very small increase in the % U937 cells in the cell aggre-
gate (Figure 5, light gray line, labeled “with vehicle”).
Inside-out activation resulted in a rapid increase in cell
aggregation during the first six minutes after mixing the
cell populations (Figure 5, black line, labeled “with fMLFF
only”). Addition of the unlabelled VLA-4 specific ligand
“LDV block” resulted in rapid cellular disaggregation, indi-
cating that the majority of aggregates were VLA-4 depen-
dent. The overall extent of activated cell aggregation was
similar to previously published data [46]. Pretreatment of
U937 cells with fMLFF, and subsequently with nitric oxide
donor, in a manner similar to the Figure 2A, abolished
fMLFF-dependent cellular aggregation (gray line, labeled
“with fMLFF and DEA-NONOate”). In fact, cell aggrega-
tion in this experiment was very similar to the aggregation
of the resting cell (untreated control). Thus, treatment of
activated cells with NO-donor only abolished the effect of
GPCR-dependent cell activation, and did not affect resting
cell aggregation. This result is additionally supported by
the LDV-FITC ligand binding kinetics data (Figure 3B,
3C). Activation of guanylyl cyclase induced a rapid
decrease of the VLA-4 ligand binding affinity to a level
that was quantitatively similar to the resting state. Thus,
the NO/cGMP signaling pathway provides an antagonistic
signal that can rapidly and actively decrease the affinity
state of the VLA-4 ligand binding pocket, and this results
in the modulation of VLA-4/VCAM-1 dependent cellular
aggregation.
Discussion
Inside-out deactivation of integrins
A current paradigm of the inside-out activation of integ-
rins implies an instantaneous triggering of integrin con-
formational changes, where a chemokine signal appears
to be closely apposed to the integrin [56]. An “updated”
adhesion cascade includes several steps in addition to
the traditional tethering, rolling, and arrest [57]. While
integrin adhesion research is largely focused on activat-
ing pathways, the inhibitory Gas-coupled GPCR/cAMP-
dependent signaling pathways is acknowledged for plate-
let regulation [58]. The relative lack of interest in the
integrin deactivation pathways is potentially compen-
sated by the identification of antagonists that competi-
tively block adhesive interactions, and thus, provide a
desirable therapeutic effect [59].
However, it is arguable that deactivation of the signal-
ing pathway is as appealing as a direct blockade of the
activating signaling using receptor antagonists. It was
established, that in order to induce a half-optimal eleva-
tion of the signal in leukocytes, only a very small frac-
tion of occupied cellular receptors is required. In some
cases, this fraction may be less than 0.1% of the total
number of receptors [60]. This is dependent on signifi-
cant signal amplification for both stimulatory and inhi-
bitory pathways [61]. Therefore, from a therapeutic
point of view, it would be very difficult to completely
block the occupancy of activating chemokine receptors
using receptor-specific antagonists. A small fraction of
activating receptors occupied by the ligand, may be suf-
ficient to trigger the adhesion signal. A plausible sce-
nario would be to take advantage of natural regulatory
pathways to counteract unwanted signaling, especially
because antagonistic pathways potentially have similar
amplification capacity [60,61].
NO-dependent VLA-4 deactivation and hematopoietic
stem cell mobilization
The VLA-4 integrin is critical for the interaction of
hematopoietic progenitors and stromal cells [2,3]. Block-
ing of the VLA-4/VCAM-1 interaction using anti-VLA-4
antibodies, small molecule competitive as well as allos-
teric VLA-4 antagonists, results in the mobilization of
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Figure 5 Changes in cell adhesion between U937 FPR (ΔST)
and VCAM-1-transfected B78H1 cells in the resting state and in
response to receptor stimulation. Real-time aggregation
experiments were conducted as described under “Methods”. U937/
ΔST FPR stably transfected cells, which constitutively express VLA-4,
were labeled with red fluorescent dye, and B78H1/VCAM-1
transfectants were stained with green fluorescent dye. Labeled cells
were preincubated for 10 min at 37°C with fMLFF only (100 nM,
activated control), DMSO (vehicle, resting cells control), or with
fMLFF and DEA-NONOate (250 μM, nitric oxide donor) in a manner
analogous to the experiment showed in Figure 2A. Next, cells were
mixed and real-time cell aggregation (red and green double
positive events) was followed. To determine the level of VLA-4
dependent cell aggregation, 6 min after cell mixing, excess
unlabelled VLA-4 specific ligand was added (arrow, LDV block, 2
μM). This induced rapid cellular disaggregation to the level of non-
specific binding. A representative experiment out of three
experiments is shown.
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Endothelial nitric oxide synthase (eNOS), one of the
major enzymes, producing nitric oxide in the vasculature,
is essential for the mobilization of stem and progenitor
cells from the bone marrow stem cell niche. Mice lacking
eNOS showed a defect in progenitor mobilization [26].
Nitric oxide synthase-derived nitric oxide regulates the
bone marrow environment, and is envisioned as a direct
mediator of cell mobilization [27]. Our current finding
that nitric oxide/cGMP signaling pathway can actively
down-regulate VLA-4 affinity, even under conditions of
constant signaling, induced by a non-desensitizing
mutant of GPCR, indicates that VLA-4 conformational
deactivation provides a plausible explanation for the
molecular basics of nitric oxide signaling-induced pro-
genitor mobilization.
Future directions
Several reports indicate that other signaling pathways
actively down-regulate integrin affinity and cell adhe-
sion. For example, cyclic cytidine 3’,5’-monophosphate
(cCMP) was shown to modulate leukocyte activation
[63], to inhibit platelet activation, and to signal through
cGMP-dependent protein kinase (PKG) [64]. Although,
the existence and metabolism of cCMP in mammals is
uncertain [65], recent report suggests that the adenylyl
cyclase toxin edema factor and adenylate cyclase-hemo-
lysin (CyaA), produced by Bacillus anthracis and Borde-
tella pertussis, can catalyze the formation of cCMP, and
other cyclic nucleotides [66]. The ability of cCMP to
down-modulate immune cell adhesion, and thus,
decrease immune response could be a part of a host
immunity subversion strategy. Nonetheless the search
for novel inside-out deactivating pathways is justified,
especially, if we would like to understand and take full
advantage of natural regulatory mechanisms that evolved
to enable anti-adhesive signaling.
Do deactivating signaling pathways operate on other
integrins? A large body of the literature suggests that
major integrins, expressed on blood cells and platelets,
behave in a similar way. Integrin-dependent platelet
aggregation and adhesion are known to be actively regu-
lated by cyclic nucleotides [67]. Cyclic AMP is known to
rapidly decrease LFA-1 dependent cell adhesion [68],
and binding of the ligand to activated LFA-1 can be
rapidly and reversible down-modulated in a manner
identical to VLA-4 [21,69]. So far the information is lim-
ited for other integrins.
Are there existing drugs in use today that take advan-
tage of these signaling pathways? The success of PDE5
inhibitors, blocking hydrolysis of cGMP, and currently
used for the treatment of erectile dysfunction stimulated
significant interest in other therapeutic applications of
the NO/cGMP-dependent signaling pathway. Studies on
different PDE inhibitors show potential in anti-inflam-
matory therapy. Currently, a large number of preclinical
in vivo studies on PDE inhibitors exhibit decreased cell
recruitment, activation of inflammatory cells and physio-
logical changes in lung function in asthma, chronic
obstructive pulmonary disease, and others [70,71].
cAMP phosphodiesterase-4 inhibitor showed anti-
inflammatory activity in vitro and in a model of psoria-
sis [72]. Thus, our finding that NO/cGMP pathway
directly regulates integrin-dependent immune cell adhe-
sion provides the rationale for repositioning of existing
drugs toward pathologies, where integrin-mediated
excessive immune cell adhesion/recruitment is envi-
sioned to be detrimental.
Conclusions
We conclude that the nitric oxide/cGMP signalling
pathway dramatically decreases the up-regulation of
VLA-4 integrin ligand-binding affinity, when triggered
prior to inside-out integrin activation, and rapidly
down-modulates VLA-4 affinity, when induced after
integrin activation. This conformational change results
in a significant down-regulation of VLA-4-dependent
cell adhesion, suggesting a major role of this pathway in
the regulation of inside-out integrin de-activation and
cell de-adhesion (mobilization).
Methods
Materials
The VLA-4 specific ligand [14,46,47] 4-((N’-2-methyl-
phenyl)ureido)-phenylacetyl-L-leucyl-L-aspartyl-L-valyl-
L-prolyl-L-alanyl-L-alanyl-L-lysine (LDV containing
small molecule), and its FITC-conjugated analog (LDV-
FITC) were synthesized at Commonwealth Biotechnolo-
gies. Human recombinant CXCL12/SDF-1a, and recom-
binant human CXCL8/IL-8 were from R&D Systems.
All other reagents were from Sigma-Aldrich. Stock solu-
tions were prepared in DMSO, at concentrations ~1000
fold higher than the final concentration. Usually, 1 μlo f
stock solution was added to 1 ml of cell suspension
yielding a final DMSO concentration of 0.1%. Control
samples were treated with an equal amount of pure
DMSO (vehicle). CXCL12/SDF-1a and CXCL8/IL-8
solutions were prepared using water, and used according
to manufacturer’s instructions.
Cell Lines and Transfectant Construct
The human histiocytic lymphoma cell line U937 and
mouse melanoma cell line B78H1 were purchased from
ATCC. Wild type CXCR4 (CD184) receptor, and
CXCR2, IL-8RB, (CD128b, CD182) stably transfected
U937 cells, and site-directed mutants of the FPR (non-
desensitizing mutant of FPR ΔST) in U937 cells were
prepared as described [73] and were a gift of Dr. Eric
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of B78H1 cells, full-length human VCAM-1 cDNA was
a kind gift from Dr. Roy Lobb of Biogen Inc. The origi-
nal construct [74] was subcloned into the pTRACER
vector (Invitrogen). Transfection into B78H1 was done
using the LipofectAMINE Reagent (Invitrogen). High
expressors were selected using the MoFlo Flow Cyt-
ometer (DakoCytomation). Cells were grown in RPMI
1640 (supplemented with 2 mm l-glutamine, 100 units/
ml penicillin, 100 g/ml streptomycin, 10 mm HEPES,
pH 7.4, and 10% heat-inactivated fetal bovine serum)
and then harvested and resuspended in 1 ml of HEPES
buffer (110 mM NaCl, 10 mM KCl, 10 mM glucose, 1
mM MgCl2, 1.5 mM CaCl2, and 30 mm HEPES, pH 7.4)
containing 0.1% human serum albumin and stored on
ice. The buffer was depleted of lipopolysaccharide by
affinity chromatography over polymyxin B sepharose
(Detoxigel; Pierce Scientific). Cells were counted using
the Coulter Multisizer/Z2 analyzer (Beckman Coulter).
For experiments, cells were suspended in the same
HEPES buffer at 1 × 10
6 cells/ml and warmed to 37°C.
Alternatively, cells were resuspended in warm RPMI
(37°C) and used immediately.
Kinetic Analysis of Binding and Dissociation of VLA-4
Specific Ligand
Kinetic analysis of the binding and dissociation of the
LDV-FITC probe was described previously [14,46].
Briefly, cells (1 × 10
6 cells/ml) were preincubated in
HEPES buffer containing 0.1% HSA or RPMI under dif-
ferent incubating conditions for 10-20 min at 37°C.
Flow cytometric data were acquired for up to 1024 s at
37°C while the samples were stirred continuously at 300
rpm with a 5 × 2 mm magnetic stir bar (Bel-Art Pro-
ducts). For real-time affinity activation experiments, 4
nM LDV-FITC was added after establishing a baseline
for unstained cells marked on figures as “autofluores-
cence”. Next, different ligands were added and acquisi-
tion was re-established, creating a 5-10 s gap in the
time course. For activation, cells were treated with dif-
ferent GPCR ligands at saturating concentration (10
times or higher than Kd). In several experiments cells
were treated sequentially with two different compounds.
Acquisition was re-established, and data were acquired
continuously for up to 1024 s. The concentration of the
LDV-FITC probe used in the experiments (4 nM) was
below the dissociation constant (Kd) for its binding to
resting VLA-4 (low affinity state, Kd ~1 2n M ) ,a n d
above the Kd for physiologically activated VLA-4 (high
affinity state, Kd ~ 1-2 nM) [14]. Therefore, the transi-
tion from the low affinity to the high affinity receptor
state led to increased binding of the probe (from ~25%
to ~70-80% of receptor occupancy, as calculated based
on the one site binding equation), which was detected
as an increase in the mean channel fluorescence (MCF).
For kinetic dissociation measurements, cell samples
were preincubated with the fluorescent probe (25 nM),
treated with excess unlabeled LDV containing small
molecule (2 μM) and the dissociation of the fluorescent
molecule was followed. The resulting data were con-
verted to MCF versus time using FCSQuery software
developed by Dr. Bruce Edwards (University of New
Mexico).
Cell Adhesion Assay
The cell suspension adhesion assay has been described
previously [46,55]. Briefly, U937/ΔST FPR stably trans-
fected cells were labeled with red fluorescent PKH26GL
dye, and B78H1/VCAM-1 transfectants were stained
with green fluorescent PKH67GL dye (Sigma-Aldrich).
Labeled cells were washed, resuspended in HEPES buffer
supplemented with 0.1% HSA and stored on ice until
used in assays. Control U937 cells were preincubated
with the 1 μM LDV-containing small molecule for
blocking adhesion. Prior to data acquisition, cells were
warmed to 37°C for 10 min separately and then mixed.
During data acquisition, the samples were stirred with a
5 × 2-mm magnetic stir bar (Bel-Art Products, Pequan-
nock, NJ) at 300 rpm and kept at 37°C. For stimulation,
cells were treated with appropriate GPCR ligands at
saturating concentration (10 times or higher than Kd).
In several experiments cells were treated sequentially
with two different compounds. The number of cell
aggregates containing U937 adherent to B78H1/VCAM-
1 (red and green cofluorescent particles) as well as the
number of singlets (red or green fluorescent particles,
FL2 and FL1 in FACScan flow cytometer) were followed
in real-time. The percentage of aggregates was calcu-
lated as follows: % U937 cells in aggregates = number of
aggregates/(number of aggregates + number of U937
singlets)) × 100. Experiments were done using a FACS-
can flow cytometer and Cell Quest software (Becton
Dickinson, San Jose, CA). The data were converted to
number of singlets/aggregates versus time using FCSQu-
ery software developed by Dr. Bruce Edwards (Univer-
sity of New Mexico).
Statistical analysis
Curve fits and statistics were performed using GraphPad
Prism (GraphPad Prism version 4.00 for Windows,
GraphPad Software, San Diego, CA). Each experiment
was repeated at least three times. The experimental
curves represent the mean of two or more independent
runs. SEM was calculated using GraphPad Prism. To
estimate the statistical significance of the difference
between control and treated samples (as Figures. 2B, 2C,
2D, 2E, and 3B, 3C), the sections of the kinetic curves at
the peak of activation and after the steady state was
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“*” for the peak and “**” for the steady state) were com-
pared using the unpaired t test (GraphPad Prism version
4.00 for Windows, GraphPad Software, San Diego, CA).
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L-leucyl-L-aspartyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-L-lysine); LDV-FITC:
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